Corrupt endothelial cells found to protect blood cancer cells from chemotherapy

byWeill Cornell Medical CollegePatient-derived-tumor-xenograft (PDX) as models of high-risk T-ALL patients. (A) Schematic representation of the generation and expansion of T-ALL PDX models. PB:

Updated on: December 21,2023 8

Corrupt endothelial cells found to protect blood cancer cells from chemotherapy

byWeill Cornell Medical CollegePatient-derived-tumor-xenograft (PDX) as models of high-risk T-ALL patients. (A) Schematic representation of the generation and expansion of T-ALL PDX models. PB:

Updated on:December 21,2023 8

Study finds carcinogen exposure makes cancer cells more susceptible to immune attack

by Liz Murphy,Massachusetts General HospitalCarcinogen-exposed cancer cells transform that nature of tumor-infiltrating macrophages from immunosuppressive (left) to immune activating agents (rig

Updated on: October 31,2023 2

Study finds carcinogen exposure makes cancer cells more susceptible to immune attack

by Liz Murphy,Massachusetts General HospitalCarcinogen-exposed cancer cells transform that nature of tumor-infiltrating macrophages from immunosuppressive (left) to immune activating agents (rig

Updated on:October 31,2023 2

Radiotherapy for hard-to-treat bladder cancer

byInstitute of Cancer ResearchCredit: Institute of Cancer ResearchMore targeted forms of radiotherapy can effectively treat bladder cancer which has spread to the lymph nodes of the pelvis, acco

Updated on: December 20,2023 16

Radiotherapy for hard-to-treat bladder cancer

byInstitute of Cancer ResearchCredit: Institute of Cancer ResearchMore targeted forms of radiotherapy can effectively treat bladder cancer which has spread to the lymph nodes of the pelvis, acco

Updated on:December 20,2023 16

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on: November 21,2023 27

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on:November 21,2023 27

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on: December 21,2023 11

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on:December 21,2023 11

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on: October 11,2023 258

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on:October 11,2023 258

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on: October 31,2023 5

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on:October 31,2023 5

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on: October 24,2023 42

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on:October 24,2023 42

Mutations in bone cells can drive leukemia in neighboring stem cells

Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children&#39

Updated on: November 02,2023 5

Mutations in bone cells can drive leukemia in neighboring stem cells

Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children&#39

Updated on:November 02,2023 5

New insight into BRCA2 gene mutations and cancer risk

A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovari

Updated on: October 31,2023 27

New insight into BRCA2 gene mutations and cancer risk

A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovari

Updated on:October 31,2023 27

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on: October 24,2023 33

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on:October 24,2023 33

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on: October 11,2023 222

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on:October 11,2023 222